The news is directly about Nautilus Biotechnology and is likely to have a neutral impact on its stock price in the short term. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's valuation of the company has not changed.